Major Depressive Disorder Clinical Trial
Official title:
Examination of the Neural Components Underlying the Treatment of Adolescent Major Depression
Verified date | February 2020 |
Source | Mclean Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of the study is to examine how cognitive behavioral therapy (CBT), a common
treatment for adolescent depression, affects brain functioning. Depressed adolescents will
complete an initial assessment consisting of an interview, questionnaires, computer tasks,
and an EEG recording. EEG (electroencephalography) measures brain activity by recording the
electrical activity along the scalp caused by the firing of neurons within the brain. They
will then complete 12 sessions of cognitive behavioral therapy, which will be 50 minutes long
and held once a week for 12 weeks. Before their third therapy session, participants will
complete a computer task while EEG data are recorded. After completing the treatment, the
participants will complete a final assessment, which will include questionnaires, computer
tasks, and an EEG recording. They will also complete follow-up assessments over the phone 1,
3, and 6 months after completing the treatment.
This study will also include healthy control participants. They will complete an initial
assessment consisting of an interview, questionnaires, computer tasks, and an EEG recording.
Three weeks later, they will return to complete a behavioral task while EEG data are
recorded. Twelve weeks after the initial assessment, they will complete a final assessment,
which will include questionnaires, computer tasks, and an EEG recording.
Status | Completed |
Enrollment | 112 |
Est. completion date | June 30, 2019 |
Est. primary completion date | June 1, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 13 Years to 18 Years |
Eligibility |
Inclusion Criteria, Major Depressive Disorder Participants: - Ages 13-18 years at time of initial assessment - Female - Current major depressive disorder (MDD) diagnosed according to the K-SADS Axis I semi-structured interview - English as first language or English fluency Exclusion Criteria, Major Depressive Disorder Participants: - Male - Mania/Hypomania - Current anxiety disorders [e.g., Panic Disorder (PD), Generalized Anxiety Disorder (GAD), Obsessive Compulsive Disorder (OCD)] - Eating Disorders - Substance Abuse/Dependency - Conduct Disorder/Antisocial Disorder - ADHD - Psychosis - Mental Retardation - Organic Brain Syndrome - Current Psychotherapy Treatment - Medical & neurological illness (head injury, loss of consciousness for more than 5 minutes, seizures) - Current use of psychotropic medication for treatment of MDD with the exception of SSRIs (selective serotonin reuptake inhibitors) - Active suicidality Inclusion Criteria, Healthy Control Participants: - Ages 13-18 years at time of initial assessment - Female - English as first language or English fluency Exclusion Criteria, Healthy Control Participants (in addition to the exclusion criteria of the MDD group): - Elevated depressive symptoms as assessed in phone screen |
Country | Name | City | State |
---|---|---|---|
United States | McLean Hospital | Belmont | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Mclean Hospital | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | EEG Activity | EEG and ERP measures collected during resting state and behavioral tasks | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |